We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

Fund managers haven’t disclosed any holdings of LCTX yet.

LCTX Hedge Fund Activity: Q1 2026 in Review

130 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q1 2026, worth a combined $176M — up 4% from $170M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new LCTX positions and 12 closed out — a net gain of 12 holders — while 37 added to existing stakes and 26 trimmed.

The largest buyer was Fifth Third Bancorp, opening a new position worth an estimated $7.76M. The largest seller was Citadel Advisors, cutting an estimated $634K.

  • 130 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q1 2026, up from 123 in Q4 2025.
  • Funds reported $176M of Lineage Cell Therapeutics stock for Q1 2026, up 4% quarter-over-quarter.
  • 24 funds opened new Lineage Cell Therapeutics positions in Q1 2026 and 12 closed out, a net change of +12 holders.
  • The largest Lineage Cell Therapeutics buyer in Q1 2026 was Fifth Third Bancorp, an estimated $7.76M added.
  • The largest Lineage Cell Therapeutics seller in Q1 2026 was Citadel Advisors, an estimated $634K sold.

Based on aggregated 13F filings for Q1 2026.